Introduction {#acel12661-sec-0001}
============

Skeletal muscle aging is characterized by progressive decline in muscle mass and function predisposing to sarcopenia, functional limitation, and metabolic dysfunction (Cruz‐Jentoft *et al*., [2010](#acel12661-bib-0004){ref-type="ref"}). Muscle aging is a multifactorial process affected by intrinsic factors such as endocrine changeover, neuronal remodeling, muscle regeneration deficiency and deterioration of cell death regulation, and extrinsic factors such as diet, physical activity, sedentariness, or other lifestyle choices (Demontis *et al*., [2013](#acel12661-bib-0005){ref-type="ref"}).

Up until loss of ovarian function at menopause, 17β‐estradiol (E~2~) is the most prominent biologically active circulating female sex hormone. Among fertile premenopausal women, the circulating serum concentration of E~2~ fluctuates from few tens of pmols L^−1^ to over 1000 pmol L^−1^ depending on a phase of the menstrual cycle (Laven & Fauser, [2006](#acel12661-bib-0017){ref-type="ref"}). Menopausal transition is characterized by irregular menstrual cycle leading eventually to amenorrhea, concomitantly with a shift in hormonal balance from higher E~2~ and lower follicle‐stimulating hormone (FSH) to constantly low E~2~ and high FSH levels (Harlow *et al*., [2012](#acel12661-bib-0012){ref-type="ref"}; Baber *et al*., [2016](#acel12661-bib-0001){ref-type="ref"}). Although sex differences in skeletal muscle metabolism and the role of ovarian hormones and benefits of postmenopausal hormone replacement therapy (HRT) in combating aging‐related decrements of muscle properties have gained a significant interest in last decades (e.g., Greising *et al*., [2009](#acel12661-bib-0009){ref-type="ref"}; Velders & Diel, [2013](#acel12661-bib-0034){ref-type="ref"}; Sipilä *et al*., [2015](#acel12661-bib-0031){ref-type="ref"}; Gheller *et al*., [2016](#acel12661-bib-0008){ref-type="ref"}), current knowledge base is overwhelmingly contributed by male studies with fewer input coming from studies concentrating on female‐specific aspects of aging.

The circulating female hormone pool is not the only hormonal pool affecting muscle properties. We have recently shown that intramuscular E~2~ concentration is associated with muscle strength and power, independently from the E~2~ concentration in the circulation (Pöllänen *et al*., [2015](#acel12661-bib-0022){ref-type="ref"}). The origin of intramuscular hormones and their exact molecular functions are currently unknown. Muscle tissue may directly respond to circulating E~2~ as well as uptake dehydroepiandrosterone (DHEA), testosterone, or other precursor hormones, to be converted to biologically active E~2~, which then contributes to the intracellular signaling. It is well documented that muscle cells express estrogen and androgen receptors enabling receptor‐dependent signaling and direct interactions with other pathways such as IGF‐1/Akt signaling (Olivieri *et al*., [2014](#acel12661-bib-0019){ref-type="ref"}). To gain a more comprehensive view on the responses of skeletal muscle to hormonal aging, multiple ‐omics approaches, including transcriptomics, proteomics, and metabolomics are desired.

Recently, a French research consortium identified 67 putative biomarkers of muscle aging by comparing muscle samples from groups of 56‐ and 78‐year‐old postmenopausal women (Gueugneau *et al*., [2014](#acel12661-bib-0010){ref-type="ref"}; Theron *et al*., [2014](#acel12661-bib-0032){ref-type="ref"}). Candidate proteins for muscle aging were classified into eight functional groups, including myofilaments and cytoskeleton, energy metabolism, detoxification, cytoprotection, signal transduction, proteostasis, proteolysis, and serum proteins. However, in these studies the role of hormone status on muscle aging was not investigated. To complement the previous investigations on aging female muscle proteome, we focused on possible differences evoked by menopause‐associated hormonal aging in adult premenopausal and middle‐aged postmenopausal women. In the current study, we investigated the age‐ and hormone status‐associated differences in female muscle proteome in relation to differences in muscle performance. We used skeletal muscle samples of premenopausal (30‐ to 34‐year‐old) women in comparison with postmenopausal (54‐ to 62‐year‐old) women who were either never exposed to or current HRT users. Moreover, we utilized a genetically controlled cotwin model to investigate the relationship between HRT and muscle proteome among postmenopausal women with, on average of 7‐year discordance, in the history of HRT use. Finally, potential differences due to different types of HRT, namely E~2~‐ or tibolone‐based product, were investigated. This approach enabled determination of differences in female muscle proteome that are associated with hormonal aging, that is, differences in age and E~2~ and pinpointing E~2~ as a major regulator of female muscle energy and cell death pathways.

Results and discussion {#acel12661-sec-0002}
======================

Clinically and phenotypically characterized female muscle samples were lysed and subjected to data‐independent nano‐LC‐HD‐MS^E^ analysis, followed by protein identification and relative abundance quantitation using the Progenesis QI for Proteomics platform. Subsequently, functional characterization using Ingenuity Pathway Analysis (IPA) software was performed. We determined the proteomic differences and the affected molecular pathways due to differences in age and hormonal status as well as predicted upstream regulators of the affected pathways. Due to differences in the functional mechanism of estrogen‐based (E~2~‐HRT) and tibolone‐based (Tib‐HRT) HRT, the proteomics analysis was performed separately for these subgroups.

Clinical characteristics of study participants {#acel12661-sec-0003}
----------------------------------------------

Study participants included six healthy 30‐ to 34‐year‐old premenopausal women and 18 women from nine pairs of 54‐ to 62‐year‐old postmenopausal monozygotic (MZ) cotwin sisters discordant for current HRT use (Ronkainen *et al*., [2009](#acel12661-bib-0025){ref-type="ref"}; Pöllänen *et al*., [2011](#acel12661-bib-0021){ref-type="ref"}). The clinical and gynecological characteristics are summarized in Table [1](#acel12661-tbl-0001){ref-type="table-wrap"}. Among the HRT using twin sisters, three used HRT medication which contained only estradiol and three a medication which included estradiol and progestogen forming the E~2~‐HRT group, while another three used tibolone‐containing HRT (Tib‐HRT group), known to possess estrogenic, progestogenic, and androgenic functions (Dubey *et al*., [2004](#acel12661-bib-0006){ref-type="ref"}; Hanifi‐Moghaddam *et al*., [2005](#acel12661-bib-0011){ref-type="ref"}). As estradiol‐only HRT and estradiol plus progestogen HRT are based on the utilization of estradiol as a main functional hormone, and there were no phenotypic differences between the users (data not shown), these two groups were combined to increase the statistical power of the proteomic analysis. All participants were in good self‐reported health, although some of them reported minor medical conditions such as allergies, musculoskeletal problems, migraine, or had hypertension with medication (Table [1](#acel12661-tbl-0001){ref-type="table-wrap"}). Furthermore, one postmenopausal woman had a history with malignant melanoma, for which she had undergone treatment for 15 years before the study onset.

###### 

Clinical data of the study participants

                                                                                                                      Premenopausal *n* = 6   Postmenopausal nonusers *n* = 9   Postmenopausal HRT users *n* = 9
  ------------------------------------------------------------------------------------------------------------------- ----------------------- --------------------------------- ----------------------------------
  Age (years)                                                                                                         31.8 ± 1.8              57.3 ± 2.2                        57.3 ± 2.2
  Health and lifestyle variables                                                                                                                                                
  Number of chronic diseases or conditions                                                                                                                                      
  Allergy (*n*)                                                                                                       4                       2                                 1
  Musculoskeletal problems (*n*)                                                                                      4                       4                                 3
  Migraine (*n*)                                                                                                      3                       1                                 0
  Cancer history (*n*)                                                                                                0                       1                                 0
  Hypertension with medication (*n*)                                                                                  0                       4                                 5
  Current smokers (*n*)                                                                                               2                       1                                 1
  Physical activity                                                                                                                                                             
  Sedentary (*n*)                                                                                                     0                       1                                 1
  Moderately active (*n*)                                                                                             3                       3                                 3
  Active (*n*)                                                                                                        3                       5                                 4
  Gynecological data                                                                                                                                                            
  Age at first menstruation (years)                                                                                   13.3 ± 2.0              12.9 ± 1.4                        12.6 ± 1.0
  Age at last menstruation (years)                                                                                    Still menstruating      48.7 ± 4.2                        50.7 ± 2.0
  Number of participants with regular menstrual cycle (*n*)                                                           6                       No cycle                          No cycle
  Mean length of the cycle (days)                                                                                     28.3                                                      
  Number of participants been pregnant (*n*)                                                                          4                       8                                 7
  Number of pregnancies per participant (*n*)                                                                         0--3                    0--3                              0--3
  Number of participants having used hormonal contraceptive during past 10 years; but not within last 5 years (*n*)   3                       1                                 1
  Number of participants with ovariectomy and/or hysterectomy (*n*)                                                   0                       1                                 3
  Number of participants reporting menopausal symptoms                                                                0                       9                                 7
  Use of HRT                                                                                                          Never                   Never                             Currently
  Duration of HRT use (years)                                                                                                                                                   7.3 ± 3.3
  Number of E~2~‐HRT users (*n*)                                                                                                                                                3
  Number of E~2~+progestogen‐HRT users (*n*)                                                                                                                                    3
  Number of Tib‐HRT users                                                                                                                                                       3

Data are presented either as mean ± standard deviation or as total number of participants. HRT = hormone replacement therapy, E~2~ = 17β‐estradiol, Tib = tibolone.
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The phenotype characteristics of the study participants are presented in Table [2](#acel12661-tbl-0002){ref-type="table-wrap"}. There were no significant differences in body composition between pre‐ and postmenopausal women, but according to handgrip strength measurements, premenopausal women were stronger than non‐HRT postmenopausal women. Premenopausal women were also more powerful than postmenopausal women regardless of the HRT status, and the HRT users had greater muscle power than their nonusing cotwins (Table [2](#acel12661-tbl-0002){ref-type="table-wrap"}). The expected menopause‐ and HRT status‐related differences were seen in systemic hormones status, namely in the circulating concentrations of E~2~, testosterone, luteinizing hormone (LH), and FSH (Table [2](#acel12661-tbl-0002){ref-type="table-wrap"}). As we have previously demonstrated (Pöllänen *et al*., [2015](#acel12661-bib-0022){ref-type="ref"}), there were no differences in intramuscular steroid hormone levels except for higher dihydrotestosterone (DHT) levels in postmenopausal HRT users and nonusers compared to premenopausal women.

###### 

Phenotype characteristics of the study participants. Statistically significant *P*‐values are marked in bold

                                                                   Premenop. Women (*n* = 6)   Postmenop. nonusers (*n* = 9)   Postmenop. HRT users (*n* = 9)   *P*‐values                  
  ---------------------------------------------------------------- --------------------------- ------------------------------- -------------------------------- ------------- ------------- -----------
  Body composition                                                                                                                                                                          
  BMI (kg m^−2^)                                                   23.1 ± 2.2                  26.9 ± 4.6                      25.4 ± 2.4                       0.082         0.079         0.261
  Waist circumference (cm)                                         80.8 ± 10.1                 90.1 ± 10.1                     85.5 ± 5.0                       0.106         0.252         0.176
  Hip circumference (cm)                                           97.0 ± 5.3                  102.6 ± 7.9                     99.8 ± 5.3                       0.156         0.338         0.074
  Body fat mass (kg)                                               15.7 ± 5.1                  23.9 ± 8.9                      19.8 ± 4.8                       0.064         0.135         0.121
  LBM (kg)                                                         43.3 ± 3.3                  44.9 ± 4.0                      45.7 ± 2.6                       0.437         0.146         0.527
  Muscle performance                                                                                                                                                                        
  Handgrip (N)                                                     333.6 ± 45.7                258.9 ± 36.1                    289.1 ± 57.0                     **0.004**     0.134         0.218
  Power (cm)                                                       26.6 ± 5.7                  12.6 ± 3.8                      15.5 ± 2.8                       **\<0.001**   **\<0.001**   **0.011**
  Specific force (N cm^−2^)                                        10.1 ± 1.8                  9.8 ± 1.7                       9.4 ± 1.5                        0.732         0.424         0.470
  Systemic hormones[a](#acel12661-note-0003){ref-type="fn"}                                                                                                                                 
  E~2~ (pmol L^−1^)                                                461.7 ± 308.2               26.0 ± 8.5                      151.0 ± 233.9                    **\<0.001**   **0.008**     **0.018**
  Testosterone (nmol L^−1^)                                        1.1 ± 0.4                   0.8 ± 0.3                       0.7 ± 0.2                        0.224         **0.050**     0.374
  DHT (pmol L^−1^)                                                 468.3 ± 319.8               201.1 ± 110.8                   268.9 ± 91.2                     **0.026**     0.181         0.141
  DHEAS (μmol L^−1^)                                               4.4 ± 1.6                   3.2 ± 1.5                       3.5 ± 1.7                        0.066         0.088         0.374
  LH (IU L^−1^)                                                    9.6 ± 5.3                   32.7 ± 15.6                     28.6 ± 6.0                       **0.001**     **0.001**     0.214
  FSH (IU L^−1^)                                                   6.2 ± 1.7                   82.9 ± 20.3                     54.9 ± 26.1                      **\<0.001**   **\<0.001**   **0.015**
  SHBG (nmol L^−1^)                                                54.2 ± 18.4                 54.1 ± 23.8                     54.3 ± 29.3                      0.689         0.864         0.767
  Intramuscular hormones[a](#acel12661-note-0003){ref-type="fn"}                                                                                                                            
  E~2~                                                             1.3 ± 0.1                   1.3 ± 0.3                       1.2 ± 0.2                        0.776         0.607         0.058
  Testosterone                                                     11.8 ± 1.8                  12.3 ± 2.5                      11.0 ± 1.6                       0.689         0.529         0.086
  DHT                                                              0.5 ± 0.1                   0.9 ± 0.2                       0.8 ± 0.1                        **\<0.001**   **\<0.001**   **0.011**
  DHEA                                                             70.1 ± 11.1                 70.7 ± 14.7                     61.9 ± 11.8                      0.776         0.224         0.110

Data are presented as mean ± standard deviation. HRT = hormone replacement therapy, BMI = body mass index, LBM = lean body mass, E~2~ = 17β‐estradiol, DHT = dihydrotestosterone, DHEA(S)  = dehydroepiandrosterone (sulfate), LH = luteinizing hormone, FSH = follicle‐stimulating hormone, SHBG = sex hormone‐binding globulin.

Due to nonlinear distribution of hormone variables, Mann--Whitney *U*‐test for independent samples was used to test significance of group means in PRE vs. nonuser and PRE vs. HRT user comparisons and Wilcoxon signed rank test for related samples to test significance of group means in HRT vs. nonuser comparison.
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To investigate the potential cotwin differences in clinical characteristics between E~2~‐HRT and Tib‐HRT groups, the mean intrapair differences within both groups were calculated (Table [3](#acel12661-tbl-0003){ref-type="table-wrap"}). Among the E~2~‐HRT group, intrapair differences existed for muscle power, systemic E~2~, sex hormone‐binding globulin (SHBG), and for intramuscular DHT while among Tib‐HRT group a significant difference between the sisters was observed in specific muscle force. E~2~‐ and Tib‐HRT groups differed from each other in specific force and systemic E~2~, testosterone, and SHBG levels. These results further confirm that E~2~‐ and Tib‐HRT have different mechanisms of function, which subsequently leads to differences in the phenotype.

###### 

The intrapair differences of postmenopausal twins. Statistically significant *P*‐values are marked in bold

                                                                   E~2~‐based HRT (*n* = 6 pairs)   Tibolone‐based HRT (*n* = 3 pairs)   Group comparison               
  ---------------------------------------------------------------- -------------------------------- ------------------------------------ ------------------ ----------- -----------
  Body composition                                                                                                                                                      
  BMI                                                              −2.78 ± 3.88                     0.140                                1.07 ± 1.59        0.363       0.152
  Waist circumference                                              −7.20 ± 10.32                    0.148                                0.67 ± 3.55.0      0.774       0.253
  Hip circumference                                                −3.78 ± 4.83                     0.114                                −0.89 ± 0.92       0.236       0.354
  Body fat mass                                                    −6.82 ± 6.76                     0.057                                1.44 ± 3.97        0.594       0.097
  LBM                                                              −0.06 ± 3.79                     0.972                                2.45 ± 2.76        0.265       0.349
  Muscle performance                                                                                                                                                    
  Handgrip                                                         25.53 ± 69.32                    0.408                                39.30 ± 77.66      0.473       0.794
  Power                                                            3.58 ± 2.89                      **0.029**                            1.41 ± 1.20        0.179       0.262
  Specific force                                                   0.48 ± 0.94                      0.268                                −2.11 ± 0.53       **0.020**   **0.003**
  Systemic hormones[a](#acel12661-note-0005){ref-type="fn"}                                                                                                             
  E~2~                                                             187.17 ± 275.10                  **0.027**                            0.67 ± 5.13        0.785       **0.024**
  Testosterone                                                     40.0 ± 95.71                     0.462                                −423.33 ± 268.39   0.109       **0.024**
  DHT                                                              0.03 ± 0.08                      0.345                                0.13 ± 0.17        0.276       0.381
  DHEAS                                                            −0.22 ± 2.01                     0.917                                1.44 ± 1.25        0.109       0.262
  SHBG                                                             25.08 ± 25.45                    **0.028**                            −49.40 ± 24.57     0.109       **0.024**
  LH                                                               −7.92 ± 10.09                    0.116                                3.73 ± 9.88        0.593       0.262
  FSH                                                              −30.98 ± 33.79                   0.075                                −22.2 ± 7.28       0.109       1.0
  Intramuscular hormones[a](#acel12661-note-0005){ref-type="fn"}                                                                                                        
  E~2~                                                             −0.11 ± 0.28                     0.399                                −0.22 ± 0.13       0.109       0.167
  Testosterone                                                     −1.18 ± 2.28                     0.345                                −1.59 ± 0.82       0.109       0.381
  DHT                                                              −0.12 ± 0.17                     **0.046**                            −0.19 ± 0.13       0.109       0.381
  DHEA                                                             −5.78 ± 17.48                    0.600                                −14.63 ± 7.38      0.109       0.262

IPD = intrapair difference, E~2~ = 17β‐estradiol, HRT = hormone replacement therapy, BMI = body mass index, LBM = lean body mass, DHT = dihydrotestosterone, DHEA(S)  =  dehydroepiandrosterone (sulfate), LH = luteinizing hormone, FSH = follicle‐stimulating hormone, SHBG = serum hormone‐binding globulin.

Due to nonlinear distribution of hormone variables, Wilcoxon signed rank test for related samples was used to test significance of intrapair difference (IPD = HRT user value -- nonuser value) within twin pairs and Mann--Whitney *U*‐test for independent samples was used to test significance of IPD between groups.
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General characterization of female muscle proteome {#acel12661-sec-0004}
--------------------------------------------------

Using nano‐LC‐HD‐MS^E^, we identified in total 1583 proteins of which 797 were quantified (Table [S1](#acel12661-sup-0001){ref-type="supplementary-material"}, Supporting information) and subjected to further analysis by applying the following scheme: (i) Postmenopausal nonhormone users (non‐HRT; *n* = 9) were compared to premenopausal women (PRE; *n* = 6), in order to identify hormonal aging‐associated differences at low E~2~ background; (ii) postmenopausal E~2~‐HRT users (*n* = 6) were compared to PRE (*n* = 6), in order to identify hormonal aging‐associated differences at E~2~‐supplemented background; and (iii) to identify HRT‐use‐associated differences at genetically controlled, same age background, two separate comparisons were made: (iii*‐*a) Postmenopausal E~2~‐HRT women (*n* = 6) were compared to their nonusing cotwins (*n* = 6); and (iii‐b) postmenopausal Tib‐HRT users (*n* = 3) were compared to their nonusing cotwins (*n* = 3).

Using this strategy and applying stringent filtering (│fold change (FC) \> 1.5│, *P* \< 0.05, ≥ 2 unique peptides observed by nano‐LC‐HD‐MS^E^) to identify differentially expressed proteins (DEPs, Table [S2](#acel12661-sup-0002){ref-type="supplementary-material"}, Supporting information), we identified hormonal aging‐associated differences in the relative abundance of 114 proteins at low E~2~ background (non‐HRT vs. PRE) and 151 proteins at E~2~‐supplemented background (E~2~‐HRT vs. PRE). Furthermore, E~2~‐HRT users differed from their non‐HRT cotwins in the relative abundance of 53 proteins, while Tib‐HRT users differed from their non‐HRT cotwins in the relative abundance of 95 proteins.

The identified DEPs were compared in order to identify unique and shared molecular processes related to age‐ and HRT‐associated differences (Fig. [1](#acel12661-fig-0001){ref-type="fig"}). When postmenopausal non‐HRT women or HRT using women were compared to the premenopausal women, 93 shared proteins were identified in both comparisons indicating that the use of HRT does not affect the age‐related differences in the abundance of these proteins (Fig. [1](#acel12661-fig-0001){ref-type="fig"}A, Table [S3](#acel12661-sup-0003){ref-type="supplementary-material"}, Supporting information). Moreover, 21 proteins were unique to non‐HRT vs. PRE comparison, and 58 to HRT users vs. PRE comparison. Furthermore, we identified 12 HRT‐associated proteins regardless the HRT type, 41 proteins specific to E~2~‐HRT, and 83 proteins specific to Tib‐HRT (Fig. [1](#acel12661-fig-0001){ref-type="fig"}B, Table [S3](#acel12661-sup-0003){ref-type="supplementary-material"}, Supporting information).

![Characterization of female muscle proteome. (A) Venn diagram comparison of differentially expressed proteins (DEPs) in relation to the differences in age with or without hormone replacement therapy (HRT) treatments. (B) Venn diagram comparison of DEPs in relation to differences in the HRT specimen (E~2~‐based or tibolone‐based). (C) Comparison of quantitative proteomics data with literature findings. Twenty‐eight proteins were identified in previous proteomic studies by Théron *et al*. and Gueaugneau *et al*., while 93 of the proteins were novel. PRE = premenopausal group, non‐HRT = postmenopausal women not using HRT, E~2~‐HRT = postmenopausal women using 17β‐estradiol‐based HRT, Tib‐HRT =  postmenopausal women using tibolone‐based.](ACEL-16-1276-g001){#acel12661-fig-0001}

As a part of our validation scheme, we compared our results and the findings of previous muscle proteomics studies on postmenopausal aging between 56 and 78 years of age (Gueugneau *et al*., [2014](#acel12661-bib-0010){ref-type="ref"}; Theron *et al*., [2014](#acel12661-bib-0032){ref-type="ref"}). Among the age‐associated DEPs (114 proteins at low E~2~ background and 151 proteins at E~2~‐supplemented background), 27 proteins have been previously described (Fig. [1](#acel12661-fig-0001){ref-type="fig"}C, Table [S3](#acel12661-sup-0003){ref-type="supplementary-material"}, Supporting information). In addition to previously known age‐associated DEPs, we identified 145 novel proteins to be associated with pre‐ to postmenopausal hormonal aging occurring between in 30--34 and 54--62 years of age. Seventy‐nine of them were present in both aging conditions with or without HRT. This indicates that although we were able to identify several novel muscle proteins with abundance influenced by aging, 54% of them were not sensitive to the use of HRT and, thus, potentially are not affected by the circulating level of E~2~. However, the use of same younger control group in both comparisons may decrease variation between comparisons and, thus, increase the similarity of the findings.

Functional muscle proteomics {#acel12661-sec-0005}
----------------------------

The lists of DEPs were subsequently functionally annotated with IPA. In total, 39 canonical pathways were found to be significantly affected (Benjamini--Hochberg adjusted *P* value, B‐H *P* \< 0.05) in one or more comparisons (Table [S4](#acel12661-sup-0004){ref-type="supplementary-material"}, Supporting information). Closer characterization of the identified pathways and their contributing proteins demonstrated grouping in three major functional clusters associated with mitochondrial functions, cytoplasmic energy metabolism, and cellular signaling linked with immune response (Fig. [2](#acel12661-fig-0002){ref-type="fig"}A).

![Functional analysis of the muscle proteome. (A) Functional distribution of differentially expressed proteins (DEPs) contributing to the canonical pathways (B) revealed substantial overlap and pinpointed the major differences in the expression to affect mitochondria (e.g., oxidative phosphorylation), cytoplasmic energy metabolism and various cellular signaling modules. (B) Canonical pathways analysis. Ten pathways with most significant Benjamini--Hochberg corrected *P*‐values are presented. PRE = premenopausal group, non‐HRT = postmenopausal women not using HRT,HRT = hormone replacement therapy, E~2~‐HRT = postmenopausal women using 17β‐estradiol‐based HRT, Tib‐HRT =  postmenopausal women using tibolone‐based, B‐H = Benjamini--Hochberg correction.](ACEL-16-1276-g002){#acel12661-fig-0002}

Among the statistically significantly affected (B‐H *P* \< 0.05) canonical pathways, ten with highest B‐H *P* values are presented in the Fig. [2](#acel12661-fig-0002){ref-type="fig"}B. Majority of the affected pathways were shared between all four conditions, but for E~2~‐HRT vs. non‐HRT, the associations were in most cases statistically nonsignificant. This may indicate that the use of E~2~‐HRT suppresses some of the aging effects. This finding is in line with our earlier transcriptomic study (Pöllänen *et al*., [2007](#acel12661-bib-0020){ref-type="ref"}), which demonstrated that the use of E~2~‐HRT mitigates genome‐wide changes in postmenopausal women\'s muscle gene expression. Significant age associations were found for 18 pathways without E~2~‐supplementation and for 18 pathways with E~2~‐supplementation in contrast to 19 pathways identified in E~2~‐HRT vs. non‐HRTs comparison, and seven pathways in Tib‐HRT vs. non‐HRT comparison (Fig. [2](#acel12661-fig-0002){ref-type="fig"}B, Table [S4](#acel12661-sup-0004){ref-type="supplementary-material"}, Supporting information). The potential protective role of HRT was not always associated with the use of Tib‐HRT. For example, glycolysis, mitochondrial dysfunction, aspartate degradation, and tricarboxylic acid (TCA) cycle pathways were significantly enriched in the Tib‐HRT vs. non‐HRT in comparison with E~2~‐HRT vs. non‐HRT (Fig. [2](#acel12661-fig-0002){ref-type="fig"}B).

Upstream regulators and downstream functions associated with female muscle {#acel12661-sec-0006}
--------------------------------------------------------------------------

In order to identify potential upstream effectors behind the observed protein level differences and to further anticipate which downstream functions are affected, we subsequently performed up‐ and downstream analyses with IPA. These analyses were based on the Ingenuity^®^ Knowledge Base regarding the associations between the multitude of upstream effectors and their targets which is combined with the measured observations, that is, our lists of DEPs.

Such analyses pinpointed E~2~ (17β‐estradiol) as one of the putative upstream effectors (Fig. [3](#acel12661-fig-0003){ref-type="fig"}A). Based on the observed alteration in muscle protein abundancies, IPA predicted E~2~ levels to be downregulated in all four comparisons except in Tib‐HRT vs. non‐HRT cotwins. To validate this prediction, E~2~ concentration was measured from muscle and serum samples in an independent set of experiments. The measured E~2~ concentration was not statistically different between groups in the muscle (Table [1](#acel12661-tbl-0001){ref-type="table-wrap"} and Fig. [3](#acel12661-fig-0003){ref-type="fig"}B); however, the concentration of circulating, systemic E~2~ in the serum followed the IPA predictions in three of four conditions (Table [2](#acel12661-tbl-0002){ref-type="table-wrap"} and Fig. [3](#acel12661-fig-0003){ref-type="fig"}C). The IPA prediction failed to reflect the order of E~2~ difference only in the E~2~‐HRT vs. non‐HRT comparison, in which the measured E~2~ level was higher in the E~2~‐HRT users as compared to the nonusers although IPA algorithm predicted it to be downregulated. E~2~‐HRT and non‐HRT women are MZ cotwins, which makes them very similar to each other. IPA cannot consider the cotwin design in the analysis; thus, the low genetic variance between groups may violate the correct prediction in the IPA\'s upstream analysis. However, several E~2~‐associated DEPs were identified for each group comparison (Fig. [4](#acel12661-fig-0004){ref-type="fig"}A--D).

![Upstream and downstream functions associated with female muscle aging with or without hormone replacement. (A) The upstream regulator analysis predicted 17β‐estradiol (E~2~) as one of the key upstream regulators behind the observed differences in muscle protein expression. (B) Fold change (FC) values of E~2~ measured from the muscle biopsy samples. The numbers at the end of the bars are *P*‐values. (C) Fold change (FC) values of the systemic E~2~ measured from the serum samples of pre‐ and postmenopausal women. The numbers at the end of the bars correspond to *P*‐values. (D) The downstream effect analysis predicted cell death, glycolysis, and muscle function pathways to be affected based on the observed differences in muscle protein expression. ROS = reactive oxygen species. (E) Comparative analysis of E~2~‐, cell death‐ and glycolysis‐associated differentially expressed proteins. IPA predicts cell death and glycolysis to be among the most affected downstream processes while E~2~ was predicted as an upstream regulator. However, the contributing DEPs for this prediction do not completely overlap. PRE = premenopausal women, non‐HRT = postmenopausal women not using HRT,HRT = hormone replacement therapy, E~2~‐HRT = postmenopausal women using 17β‐estradiol‐based HRT, Tib‐HRT = postmenopausal women using tibolone‐based HRT. The number of contributing DEPs is indicated.](ACEL-16-1276-g003){#acel12661-fig-0003}

![Comparative analysis of 17β‐estradiol (E~2~) regulated differentially expressed proteins (DEPs). (A) The DEPs identified in postmenopausal women without hormone replacement (HRT) in comparison with premenopausal women (non‐HRT vs. PRE). (B) Comparison of E~2~‐regulated DEPs among postmenopausal E~2~‐HRT users and premenopausal women (E~2~‐HRT vs. PRE). (C) Comparison of the E~2~‐regulated DEPs in postmenopausal E~2~‐HRT users and their nonusing cotwins (E~2~‐HRT vs. non‐HRT). (D) E~2~‐regulated DEPs in the postmenopausal Tib‐HRT users in comparison with their nonusing cotwins (Tib‐HRT vs. non‐HRT). The DEPs associated with the predicted downstream functions related to cell death and glycolysis as well as associated with mitochondrial functions are presented. Blue stars indicate DEPs with expression change validated by semi‐quantitative immunoblotting. ML = my lists are assembled by including all the observed DEPs involved in the corresponding pathways in any of the four conditions. ML: cell death and ML: glycolysis, originate from the analysis presented in the Fig. [3](#acel12661-fig-0003){ref-type="fig"}D, while ML: mitochondrial functions from the canonical pathways oxidative phosphorylation and mitochondrial dysfunction presented in the Fig. [2](#acel12661-fig-0002){ref-type="fig"}B. Arrows indicate the predicted inhibition or activation of the entire cascade.](ACEL-16-1276-g004){#acel12661-fig-0004}

The predicted downstream functions pointed to cell death and glycolytic pathways (Fig. [3](#acel12661-fig-0003){ref-type="fig"}D), which complements the canonical pathways analyses identifying glycolysis/gluconeogenesis as well as oxidative phosphorylation/mitochondrial dysfunctions among others to be affected by aging and use of HRT (Fig. [2](#acel12661-fig-0002){ref-type="fig"}). To get further insight and to verify that E~2~ is one of the key players for the predicted change in downstream cellular functions, we compared the proteins known to be associated with E~2~ (Fig. [4](#acel12661-fig-0004){ref-type="fig"}A--D) with proteins contributing to the cell death and glycolysis pathways (Fig. [3](#acel12661-fig-0003){ref-type="fig"}E), and identified 22 shared proteins with E~2~ and cell death pathways, two associated with E~2~ and glycolysis and two shared between all three lists. These results are supported by the measured muscle phenotype observations (Tables [2](#acel12661-tbl-0002){ref-type="table-wrap"} and [3](#acel12661-tbl-0003){ref-type="table-wrap"}), which show uppermost muscle performance with highest levels of circulating E~2~, that is, in the premenopausal women and lowest muscle performance among non‐HRT women who concomitantly had the lowest circulating E~2~ level. Furthermore, these results indicate that aging‐associated decrements in muscle function may be mediated by cell death and glycolytic pathway‐associated DEPs and to be partially E~2~‐regulated.

Functional validation of differentially expressed protein targets associated with estradiol {#acel12661-sec-0007}
-------------------------------------------------------------------------------------------

To complement and functionally validate the bioinformatics analyses, which identified E~2~ as significant upstream regulator of the muscle functions, we performed *in vitro* experiment with human muscle primary cells. Muscle progenitor cells were induced to differentiate from single nucleated myoblasts to multinucleated myotubes, which were then exposed to the E~2~. To follow the observed differences in the MS^E^ analyses on the cellular level, we confirmed the expression of selected E~2~‐associated DEPs by semi‐quantitative Western blotting from the myotubes exposed to mock conditions, and to 10 n[m]{.smallcaps} E~2~ or 100 n[m]{.smallcaps} E~2~ for 6 h.

We selected two DEPs predicted to be upregulated with lower E~2~ (non‐HRT vs. PRE and E~2~‐HRT vs. PRE) for validation. These proteins were aldolase fructose‐bisphosphate A (ALDOA) and cullin 4A (CUL4A), with important functions in energy pathways and in the regulation of cell cycle. ALDOA is a glycolytic enzyme that catalyzes the reversible conversion of fructose‐1.6‐bisphosphate to glyceraldehyde 3‐phosphate and dihydroxyacetone phosphate (Hittel *et al*., [2005](#acel12661-bib-0013){ref-type="ref"}), while CUL4A is E3 ubiquitin ligase with oncogenic effects through modulation of cell growth and immune response (Saucedo‐Cuevas *et al*., [2014](#acel12661-bib-0028){ref-type="ref"}). Furthermore, three DEPs predicted to be downregulated with lower E~2~ were also selected for semi‐quantitative analysis. These included lactate dehydrogenase A (LDHA), mitochondrial cytochrome c oxidase II (MT‐CO2), and muscle pyruvate kinase (PKM), which all have connections to muscle energy metabolism. Muscle LDHA catalyzes the conversion of lactate to pyruvate in the final step of anaerobic glycolysis (Kolappan *et al*., [2015](#acel12661-bib-0015){ref-type="ref"}). MT‐CO2 is the component of mitochondrial respiratory chain. Mutations in MT‐CO2 lead to MELAS, a multisystem disorder characterized by mitochondrial myopathy, lactic acidosis, and stroke‐like episodes followed by seizures, recurrent headaches, and muscle weakness (Rossmanith *et al*., [2009](#acel12661-bib-0026){ref-type="ref"}). The expression of PKM, which catalyzes the rate‐limiting final step in glycolysis, has been shown to be induced by E~2~ having critical role in metabolic reprogramming of proliferating cells toward aerobic glycolysis (Salama *et al*., [2014](#acel12661-bib-0027){ref-type="ref"}). Taken together, ALDOA, PKM, and LDHA have shared functions in glycolysis and cell death pathways while CUL4A and MT‐CO2 play a role in cell death.

The immunoblotting with ALDOA and CUL4A antibodies demonstrated a statistically significant change in protein expression upon treatment with 100 n[m]{.smallcaps} E~2~ (mock vs. E~2~; FC = 1.3, *P* = 0.01 for ALDOA and FC = 1.9, *P* = 0.007 for CUL4A), corroborating the results of HD‐MS^E^ (Fig. [5](#acel12661-fig-0005){ref-type="fig"}). Similarly, to the result of proteomic survey, immunoblotting with PKM antibody, which was predicted to be downregulated by IPA, demonstrated a trend for downregulation (mock vs. low E~2~; FC = −1.3); however, the difference between treatments was not statistically significant. Upon 10 n[m]{.smallcaps} E~2~ treatment, LDHA expression increased by 1.2‐fold (*P* = 0.033), while MT‐CO2 by 1.5‐fold, which however was not statistically significant. The observed discrepancy for LDHA and MT‐CO2 with corresponding proteomics measurements indicates that either longer E~2~ exposure time might be required to downregulate LDHA and MT‐CO2 expression in the muscle primary cells or other, yet unidentified factors, which are not represented *in vitro*, play a role in this process in the skeletal muscle tissue.

![Validation of the proteomic results by semi‐quantitative Western blotting in primary human muscle cells. Representative images of the Western blots from cell culture experiments with human muscle primary cells. Quantification of the immunoblots was performed with three independent cell experiments exposed to the statistical testing using independent samples *t*‐test. Data are presented as mean ± standard deviation. M = mock, 10 = 10 n[m]{.smallcaps} E~2~, 100 = 100 n[m]{.smallcaps} E~2~.](ACEL-16-1276-g005){#acel12661-fig-0005}

Concluding remarks {#acel12661-sec-0008}
==================

Female aging is characterized by menopausal change in sex steroid hormones concomitant to increase in aging‐related decrements in skeletal muscle performance that can be attenuated by HRT use (Sipilä *et al*., [2015](#acel12661-bib-0031){ref-type="ref"}). The molecular mechanisms underpinning menopausal decrements in muscle function are poorly known. Our label‐free proteomic analyses have resulted in the quantification of 797 muscle proteins. Among those identified, 27 have been formerly investigated in large‐scale female muscle proteome studies (Gueugneau *et al*., [2014](#acel12661-bib-0010){ref-type="ref"}; Theron *et al*., [2014](#acel12661-bib-0032){ref-type="ref"}), while 145 were now described for the first time to our knowledge. Among the identified novel DEPs, 79 were measured in both aging conditions, with or without HRT, indicating them to be age‐responsive and insensitive to the use of HRT. In addition, 17 novel proteins were differentially expressed in postmenopausal women without HRT and 49 with HRT in comparison with the premenopausal women.

The major canonical pathways found to be differentially regulated included mitochondrial dysfunction, oxidative phosphorylation, glycolysis, and TCA‐cycle, strong indicators for affected energy metabolism. The major biological processes predicted to be affected were related to cell death, apoptosis, and cell survival, as well as contractility of the muscle and glycolysis. Furthermore, E~2~ was predicted to be an upstream regulator of these processes, which we confirmed by exposing myotubes to E~2~ *in vitro*. Previous experimental animal studies have implicated E~2~ in mitochondrial functions and metabolic homeostasis in skeletal (Capllonch‐Amer *et al*., [2014](#acel12661-bib-0002){ref-type="ref"}; Cavalcanti‐de‐Albuquerque *et al*., [2014](#acel12661-bib-0003){ref-type="ref"}; Ribas *et al*., [2016](#acel12661-bib-0024){ref-type="ref"}), and cardiac muscle (Rattanasopa *et al*., [2015](#acel12661-bib-0023){ref-type="ref"}; Sbert‐Roig *et al*., [2016](#acel12661-bib-0029){ref-type="ref"}). In addition, previous studies have shown E~2~ to exert anti‐apoptotic effects in muscle progenitor cells by improving mitochondrial function (La Colla *et al*., [2013](#acel12661-bib-0016){ref-type="ref"}).

Being in line with previous experimental studies, our study suggests, for the first time at human proteome level, that E~2~ is a major regulator of human skeletal muscle signaling in women. After menopause, when ovarian E~2~ production is ceased, the prevalence of cardio‐metabolic diseases increases. Our result that different trajectories of the energy pathways in the skeletal muscle may be regulated by E~2~ provides candidate molecules as key targets for future interventions to prevent or treat postmenopausal metabolic dysregulation. Further studies should focus on validation of the pathways identified in this study, to corroborate E~2~ as their direct upstream regulator.

Experimental procedures {#acel12661-sec-0009}
=======================

Subjects and study design {#acel12661-sec-0010}
-------------------------

The participants represented part of the SAWEs study, for which the details of recruitment and data collection have been reported earlier (Ronkainen *et al*., [2009](#acel12661-bib-0025){ref-type="ref"}; Pöllänen *et al*., [2011](#acel12661-bib-0021){ref-type="ref"}). The current study utilizes data and skeletal muscle (*m. vastus lateralis*) samples of six healthy premenopausal women and 18 healthy women from nine pairs of postmenopausal monozygotic cotwin sisters. Premenopausal women were recruited by postal enquiry sent to two thousand women randomly selected from the entire 30‐ to 40‐year‐old age cohort (born in 1967--1977) living in the City of Jyväskylä, Finland. Among the respondents, 59 were eligible after consideration of exclusion criteria (i.e., ongoing or previous (past 5 years) use of hormonal contraceptives, pregnancy, or breastfeeding). Six (10%) were selected at random for the current proteomic study (PASW Statistical Software, SPSS Inc., IBM, IL, USA). Postmenopausal women were recruited from the Finnish Twin Cohort (Kaprio & Koskenvuo, [2002](#acel12661-bib-0014){ref-type="ref"}). Postmenopausal twin pairs aged 54--62 years were asked to participate in SAWEs study if the other cosister had never used HRT and the other was a current HRT user. Total of 15 monozygotic twin pairs met the inclusion criteria and were willing to participate as described earlier (Ronkainen *et al*., [2009](#acel12661-bib-0025){ref-type="ref"}). Twin pairs were discordant for the HRT including nine non‐HRT users and their nine cotwins currently using HRT. This study was approved by the Local Ethical Committee of the Central Finland Hospital District (E0606/06) and performed following guidelines of the Helsinki Declaration and good clinical and scientific practice. All study participants provided written informed consent.

Study participants went through a medical examination during which a physician confirmed their general health status, gynecological history, absence of possible chronic or acute illnesses, and use of medication. Data on current and past smoking, alcohol consumption, and physical activity habits were collected with a standard questionnaire. Anthropometric and body composition measurements were performed between 07:00 and 10:00 after overnight fasting and were after standardized breakfast followed by muscle strength and power measurements. Body weight was measured with beam scale and height with a stadiometer and body mass index (BMI) calculated (weight, \[kg\]/height \[m^2^\]). Waist circumference was measured midway between *spina iliaca superior* and the lower rib margin and hip circumference at the level of the greater trochanters. Body fat mass and lean body mass (LBM) were measured with a multifrequency bioelectrical impedance analyzer (InBody 720; Biospace, Seoul, Korea). Maximal handgrip force was measured with an adjustable dynamometer chair (Good Strength, Metitur, Palokka, Finland). The explosive lower body muscle power, that is, ability to produce force as quickly as possible, was assessed with counter movement jump on a contact mat. Maximal isometric knee extension force was measured in a sitting position using an adjustable dynamometer chair (Good Strength, Metitur, Palokka, Finland). In all measurements, three to five trials were allowed and the maximal performance was accepted as the result. Quadriceps muscle cross‐sectional area was assessed from the computed tomography scans (Siemens Somatom Emotion Scanner; Siemens, Erlangen, Germany) and used to calculate specific force as maximal isometric knee extension force divided by muscle cross‐sectional area (Pöllänen *et al*., [2011](#acel12661-bib-0021){ref-type="ref"}).

Blood and skeletal muscle samples and hormone assessments {#acel12661-sec-0011}
---------------------------------------------------------

Blood samples were taken between 08:00 and 10:00 h in standardized fasting conditions at supine position. For premenopausal women, samples were collected during 1‐5 days of estrous cycle. Muscle biopsies were taken following blood sampling from the mid‐part of the *m. vastus lateralis*. Visible blood, fat, and connective tissue were removed before the biopsy sample was mounted on the cork with Tissue Tek Optimal Cutting Temperature compound (OCT, Sakura; Alphen aan dae Rijn, the Netherlands), frozen rapidly in 2‐methylbutane (Sigma‐Aldrich Corporation, St. Louis, MO, USA) precooled to −160 °C in liquid nitrogen, and stored at −80 °C until used for protein analysis. Serum and muscle hormone assessments were carried out as in (Pöllänen *et al*., [2011](#acel12661-bib-0021){ref-type="ref"}). Briefly, serum concentrations of sex hormone‐binding globulin (SHBG), dihydroepiandrosterone sulfate (DHEAS), follicle‐stimulating hormone (FSH), and luteinizing hormone (LH) were measured using solid‐phase, chemiluminescent immunometric assays (Immulite 1000, Diagnostic Products, Los Angeles, CA, USA). Serum 17β‐estradiol (E~2~) was determined using an extraction radioimmunoassay, while testosterone and dihydrotestosterone (DHT) were measured separately using LC‐MS/MS. Muscle samples were homogenized on ice in Tissue Extraction Reagent I (Invitrogen, Carlsbad, CA, USA) supplemented with protease and phosphatase inhibitors. The amount of total soluble protein was determined using Pierce BCA Protein Assay‐kit (Thermo Scientific, Rockford, IL, USA). Muscular E~2~, testosterone, DHT, and DHEA concentrations were determine using ELISA tests (IBL‐international, Hamburg, Germany) from 1:10 diluted muscle supernatants in duplicates. The concentrations of muscular hormones were expressed as nmol × g^−1^ soluble muscle protein.

Sample preparation and proteolytic digestion of proteins from muscle samples {#acel12661-sec-0012}
----------------------------------------------------------------------------

Frozen muscle samples were thawed on ice, detached from cutting block, and submersed in milliQ water to wash excess amounts of OCT. Subsequently, they were dipped in 4% SDS/0.1 [m]{.smallcaps} Tris pH 8/0.05 [m]{.smallcaps} DTT and homogenized at room temperature using tissue homogenizer. The homogenate was heated for 10 min at near 100 °C and cleared by centrifugation at 30 000 *g* for 15 min. The protein concentration was determined using the nanodrop technique. 10 μg of total protein was digested, using modified FASP protocol (Scifo *et al*., [2015](#acel12661-bib-0030){ref-type="ref"}). In brief, the lysate buffer was exchanged by washing it several times with 8 [m]{.smallcaps} urea, 0.1 [m]{.smallcaps} Tris, pH 8 (urea buffer, UB). The proteins were alkylated with 50 m[m]{.smallcaps} iodoacetamide in UB, after washing out the DTT‐containing solution. 1:50 w/w of lysine‐C endopeptidase (Wako) was added in about 4 [m]{.smallcaps} urea/0.1 [m]{.smallcaps} Tris pH 8 and incubated at room temperature overnight. The peptide digests were collected by centrifugation, and trypsin solution was added in a ratio of 1:50 w/w in 50 m[m]{.smallcaps} ammonium bicarbonate. As before, the digests were collected and combined. The peptide samples were cleaned using C18---reverse phase ZipTip™ (Millipore), resuspended in 1% TFA and sonicated in water bath for 1 min.

Liquid chromatography high‐definition tandem mass spectrometry {#acel12661-sec-0013}
--------------------------------------------------------------

The samples were analyzed in randomized order. 300 ng of digested proteins/replicate (three technical replicates per sample) was used in nano‐LC‐HD‐MS^E^ analysis. The nano‐LC‐HD‐MS^E^ analyses were performed as described (Mäkelä *et al*., [2016](#acel12661-bib-0018){ref-type="ref"}; Tikka *et al*., [2016](#acel12661-bib-0033){ref-type="ref"}). Briefly, the peptides were separated by nanoAcquity UPLC system (Waters) equipped with a trapping column (5 μm Symmetry C18 180 μm × 20 mm C18 reverse phase, Waters), and followed by an analytical C18 BEH130 reversed‐phase column (75 μm × 250 mm, particle size 1.7 μ[m]{.smallcaps}; Waters) in a single pump trapping mode. After trapping, the peptides were separated with a linear gradient of 3--35% of solution B (0.1% formic acid/acetonitrile), for 90 min at a flow rate 0.3 μL min^−1^ and stable column temperature of 35 °C. Each sample run was followed by two empty runs to wash out any remaining peptides from previous runs. The samples were run in ion mobility‐assisted data‐independent analysis mode (HD‐MS^E^), in a Synapt G2‐S mass spectrometer (Waters), by alternating between low collision energy (6V) and high collision energy ramp in the transfer compartment (20--45 V) and using 1 s cycle time. The separated peptides were detected online with mass spectrometer, operated in positive, resolution mode in the range of *m/z* 50--2000 amu. 150 fmol μL^−1^ of human \[Glu^1^\]‐fibrinopeptide B (Sigma) in 50% acetonitrile/0.1% formic acid solution at a flow rate of 0.3 μL min^−1^ was used for a lock mass correction, applied every 30 s.

Database mining of proteomics data {#acel12661-sec-0014}
----------------------------------

Relative quantification between samples using precursor ion intensities was performed with Progenesis QI™ Informatics for Proteomics software (Nonlinear Dynamics/Waters) and ProteinLynx Global Server (PLGS V3.0). HD‐MS^E^ parameters were set as follows: low energy threshold of 135 counts, elevated energy threshold of 30 counts, and intensity threshold of precursor/fragment ion cluster 750 counts. Chromatograms were automatically aligned by the Progenesis QI™ software, and those with alignment score ≥70% to the reference run were selected for further analysis. All spectra were manually checked following alignment, and additional vectors were added to improve the scoring. The percentage of rejected runs was \<5%. To compare the controls to other subjects, we utilized the *between‐subject* design scheme of Progenesis QI™ software.

Database searches were carried out against UniProt‐SwissProt reviewed human database (release 2017_6, 48614 entries) with Ion Accounting algorithm as described (Mäkelä *et al*., [2016](#acel12661-bib-0018){ref-type="ref"}; Tikka *et al*., [2016](#acel12661-bib-0033){ref-type="ref"}). Following parameters were used: peptide and fragment tolerance: automatic, maximum protein mass: 500 kDa, min fragment ions matches per protein ≥7, min fragment ions matches per peptide ≥3, min peptide matches per protein ≥1, primary digest reagent: trypsin, missed cleavages allowed: 2, fixed modification: carbamidomethylation C, variable modifications: deamination of N/Q residues, oxidation of Methionine (M), and false discovery rate (FDR) \<4%. Protein quantitation was performed entirely on nonconflicting *Homo sapiens* identifications, using precursor ion intensity data and standardized expression profiles. Protein was considered to be identified when it was present in all three replicates of the nano‐LC‐HD‐MS^E^ runs and within a study group when identification failed in less than in 33% of the participants (i.e., protein called present at least four of six participants within premenopausal group and at least seven of nine participants within postmenopausal group).

Functional analysis of proteomics data {#acel12661-sec-0015}
--------------------------------------

DEPs (*P* \< 0.05 by ANOVA for all comparisons), which were quantified based on ≥2 unique peptides, served as inputs into IPA (Ingenuity Systems, Redwood City, CA; [www.ingenuity.com](http://www.ingenuity.com)). Prior to network and other functional analyses, the list of proteins was filtered to include only proteins with fold changes, FC greater than \|1.5\|. The IPA right‐tailed Fisher\'s exact test with B‐H multiple testing corrections was used to determine a *P*‐value of significance in all functional analyses.

Functional validation of proteomics data {#acel12661-sec-0016}
----------------------------------------

Primary human muscle cell line that was derived from the quadriceps muscle biopsy of a 5‐day‐old female infant (Edom *et al*., [1994](#acel12661-bib-0007){ref-type="ref"}) was kindly provided by Profs Moyly and Buttler‐Browne (INSERM, Paris, France). Proliferating mononuclear myoblasts were differentiated for 5 days to form multinuclear myotubes in E~2~ free environment, before exposing them to 10 n[m]{.smallcaps} E~2~, 100 n[m]{.smallcaps} E~2~ or mock for 6 h. All experiments were carried out in triplicate. Semi‐quantitative immunoblotting analysis was carried out to quantitate the protein expression of CUL4A, MT‐CO2, LDHA, ALDOA, and PKM. TUBA was used for normalization. The blots were scanned and quantified using Odyssey CLX Infrared Imager of Li‐COR and manufacturer\'s software. Cell culture mediums, fetal bovine serum, and antibiotics were obtained from Life Technologies, Inc. (Carlsbad, CA, USA) while insulin from Sigma‐Aldrich. CUL4A, MT‐CO2, and LDHA antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA), ALDOA and PKM from Abcam (Cambridge, UK) and TUBA from Sigma‐Aldrich. As a secondary antibodies, anti‐rabbit IR Dye 800 or anti‐mouse IR Dye 680 (LI‐COR Biosciences, Lincoln, NE, USA) was used.

Statistics {#acel12661-sec-0017}
----------

Statistical testing regarding phenotype variables and cell experiment was carried out with SPSS version 24 (IBM, Chicago, IL, USA). Shapiro--Wilk test and visual inspection of the normality plots were used to inspect normal distribution of the variables. Based on distribution, either independent samples *t*‐test or Mann--Whitney *U*‐test (in case of unrelated groups) or paired‐samples *t*‐test or Wilcoxon signed rank test (in case of twin pairs) were used.

Accession numbers {#acel12661-sec-0018}
=================

The proteome data reported in this study are available in the Proteomics IDEntifications (PRIDE) data repository under accession number PXD006446 (Vizcaíno et al., [2016](#acel12661-bib-0050){ref-type="ref"}).
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